How long does it take to take Capisetinib/Caposetinib?

CapivasertibTablets/Capivasertib (Capivasertib) is an oral, selective AKT kinase inhibitor, mainly used to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with specific gene mutations. It blocks the growth, proliferation and anti-apoptosis process of tumor cells by inhibiting the AKT signaling pathway, and is highly targeted for breast cancer with abnormal PI3K/AKT/PTEN pathway. According to the latest guidelines, its recommended usage is 400 mg orally taken twice a day for 4 consecutive days, followed by 3 days of drug withdrawal as a cycle, that is, an intermittent dosing method of "4 days of medication + 3 days of medication rest". This medication regimen has been proven in multiple clinical studies to be easier to tolerate and does not affect the efficacy.

Regarding the duration of treatment, there is currently no fixed endpoint, but is determined based on the patient's disease control, tolerance of adverse reactions, and tumor progression assessment results. Generally speaking, if a patient responds well to Capisete tablets and has no obvious side effects, doctors will recommend continued treatment until disease progression or irreversible adverse events occur. Because this drug belongs to the category of targeted therapy, its application logic is more similar to chronic disease management, emphasizing long-term precise intervention rather than short-term control, so its treatment course often spans several months or even more than a year.

In addition, sinceCapivasertib is often used in combination with fulvestrant, and its efficacy depends on the synergy of the two drugs. Therefore, fulvestrant must be used simultaneously in strict accordance with the doctor's recommendations during the entire course of treatment. Clinically, some patients can significantly delay tumor progression after receiving treatment for several months, while other patients may develop drug resistance after a few cycles. At this time, the treatment plan should be changed in time or chemotherapy and other methods should be added.

In summary, the treatment course of capositinib is not static, but dynamic and individualized. Most patients will clinically evaluate their response and tolerance on a periodic basis, and continue taking the drug for several months to a year or even longer if it is effective and safe. Adherence to regular medication and regular follow-up visits are the keys to achieving the best therapeutic effect.

Reference materials:https://www.drugs.com/mtm/capivasertib.html